CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).

被引：0
|
作者：
Li, Roger
Steinberg, Gary D.
Uchio, Edward M.
Lamm, Donald L.
Shah, Paras
Kamat, Ashish M.
Bivalacqua, Trinity
Packiam, Vignesh T.
Chisamore, Michael Jon
McAdory, John
Grandi, Paola
Hnat, Nataliya
Burke, James
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, Tampa, FL USA
[2] Univ Chicago Med, Dept Surg, Chicago, IL USA
[3] Univ Calif Orange, Irvine Med Ctr, Orange, CA USA
[4] BCG Onc, Phoenix, AZ USA
[5] Mayo Clin, Rochester, MN USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[7] Johns Hopkins Univ Hosp, Baltimore, MD USA
[8] Univ Iowa, Dept Urol, Iowa City, IA USA
[9] Merck Co & Inc, Kenilworth, NJ USA
[10] CG Oncol, Irvine, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4597
引用
收藏
页数：1
相关论文
共 50 条
  • [41] HEALTHCARE RESOURCE USE (HCRU) OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS POST BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE STATUS IN MULTIPLE COUNTRIES
    Broughton, E.
    Chun, D.
    Gooden, K.
    Mycock, K.
    Rajkovic, I
    Taylor-Stokes, G.
    [J]. VALUE IN HEALTH, 2020, 23 : S484 - S485
  • [42] Updated Interim Analysis from Keynote-057: Pembrolizumab Monotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
    Krieger, Laurence
    de Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 52 - 53
  • [43] Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: Implications for Clinical Trial Design. Reply
    Hensley, Patrick J.
    Kamat, Ashish M.
    [J]. JOURNAL OF UROLOGY, 2021, 206 (06): : 1528 - 1528
  • [44] Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guerin: Implications for Clinical Trial Design EDITORIAL COMMENTS
    Matulewicz, Richard S.
    Steinberg, Gary D.
    [J]. JOURNAL OF UROLOGY, 2021, 205 (06): : 1619 - 1620
  • [45] A Phase 1b Study of CG0070 combined with nivolumab in cisplatin ineligible patients with muscle invasive bladder cancer
    Li, Roger
    Sexton, Wade
    Spiess, Phillipe
    Gilbert, Scott
    Pow-Sang, Julio
    Zhang, Jingsong
    Borjas, Gustavo
    Grandi, Paola
    Burke, James
    Jain, Rohit
    Conejo-Garcia, Jose
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [46] Phase 2 KEYNOTE-057 cohort C: Coformulations of pembrolizumab (Pembro) and favezelimab or vibostolimab for patients with Bacillus Calmette-Guerin (BCG)-unresponsive High-Risk (HR) Non-Muscle-Invasive Bladder Cancer (NMIBC)
    Gupta, S.
    Kulkarni, G.
    Necchi, A.
    Shore, N. D.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    [J]. EUROPEAN UROLOGY, 2024, 85 : S433 - S433
  • [47] Interim results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
    Li, Zhiyong
    He, Liru
    Yao, Kai
    Ye, Yunlin
    Li, Xiangdong
    Qin, Zike
    Han, Hui
    Zhou, Fangjian
    Liu, Zhuowei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
    Li, Zhiyong
    He, Liru
    Li, Xiangdong
    Yao, Kai
    Liu, Yang
    Qin, Zike
    Ye, Yunlin
    Zhou, Fangjian
    Liu, Zhuowei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [49] A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guerin?Naive Nonmuscle-Invasive Urothelial Carcinoma of the Bladder EDITORIAL COMMENT
    Bharadwaj, Maheetha
    Koehne, Elizabeth L.
    [J]. JOURNAL OF UROLOGY, 2024, 212 (01): : 103 - 103
  • [50] CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 12 MONTH INTERIM RESULTS FROM A MULTICENTER PHASE II TRIAL
    Packiam, Vignesh T.
    Barocas, Daniel A.
    Chamie, Karim
    Davis, Ronald L., III
    Kader, A. Karim
    Lamm, Donald L.
    Gutheil, John
    Kuan, Arthur
    Steinberg, Gary D.
    [J]. JOURNAL OF UROLOGY, 2018, 199 (04): : E1166 - E1166
12345